Acorda Therapeutics (ACOR) Announces Publication of New Data on Impact of Mobility Impairment Due to Multiple Sclerosis
5/21/2013 10:05:55 AM
More...
|
Acorda Therapeutics (ACOR) Announces Issuance of Additional U.S. Patent for AMPYRA® Covering a Range of Dosage Strengths
5/20/2013 10:45:24 AM
More...
|
Acorda Therapeutics (ACOR)’ Legal Department Recognized on Best Legal Departments List by Corporate Counsel Magazine
5/17/2013 9:54:04 AM
More...
|
Acorda Therapeutics (ACOR) Announces Data Showing Dalfampridine Improves Motor Function in Preclinical Model of Post-Stroke Deficits Published in Stroke
5/9/2013 10:47:36 AM
More...
|
Acorda Therapeutics (ACOR) to Present at the Bank of America (BAC) Merrill Lynch 2013 Health Care Conference
5/9/2013 7:47:00 AM
More...
|
Acorda Therapeutics (ACOR) Recognized as One of the Best Places to Work in New York State for Third Consecutive Year
5/6/2013 10:00:39 AM
More...
|
Acorda Therapeutics (ACOR) Reports First Quarter 2013 Financial Results
5/2/2013 8:10:27 AM
More...
|
Acorda Therapeutics (ACOR) to Host Conference Call to Discuss First Quarter 2013 Financial Results on May 2, 2013
4/25/2013 8:56:02 AM
More...
|
Acorda Therapeutics (ACOR) Drug Helps Stroke Patients Walk Better
4/15/2013 7:38:41 AM
More...
|
Acorda Therapeutics (ACOR) Release: Diazepam Nasal Spray Demonstrates Comparable Bioavailability to Diazepam Rectal Gel in Pharmacokinetic Study
3/20/2013 9:34:13 AM
More...
|
|